39 results about "Diethyl fumarate" patented technology

The invention discloses a lithium titanate battery, and relates to the technical field of batteries. The battery comprises a positive electrode, a negative electrode, an electrolyte and a diaphragm, and an addition product synthesized by dimethyl fumarate and benzidine according to a specific molar ratio is added into the electrolyte as a viscosity modifier, so that the viscosity increasing trend of the electrolyte at a low temperature is effectively reduced, and the migration rate of lithium ions is improved. And the electrolyte also comprises a lithium salt, an organic solvent and an auxiliary additive, so that the low-temperature performance and the cycling stability of the battery are favorably optimized. A positive active material is one or more of lithium iron phosphate, lithium manganate, lithium cobalt oxide or nickel manganese cobalt ternary materials, a negative active material is lithium titanate, and additives such as lithium nitrate and fluoroethylene carbonate are further combined, so that the capacity retention ratio and the charge-discharge efficiency of the battery in an extreme low-temperature environment of-40 DEG C are remarkably improved. The lithium titanate battery provided by the invention has excellent low-temperature adaptability, safety and long cycle life, and is applicable to power batteries and energy storage systems in alpine regions.

This disclosure relates to uses of fumaric acid, fumaric acid esters, dimethyl fumarate, monomethyl fumarate ester, salt, or derivatives thereof by pulmonary administration in the treatment, prevention, or reversal of fibrosis e.g., pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF). In certain embodiments, this disclosure relates to treating a subject with fumaric acid, fumaric acid esters, dimethyl fumarate, monomethyl fumarate ester, salt, or derivatives inhibiting TGF-mediated pro-fibrotic phenotypes. In certain embodiments, the subject is a human of an advanced age.

The present disclosure provides methods of treating multiple sclerosis (MS) using Compound 1 represented by the following structure, or a pharmaceutically acceptable salt thereof, in combination with dihydroxymethyl fumarate (DRF).

In one or more embodiments, the present invention provides a low molecular weight, non-toxic, resorbable poly(ethylene glycol) (PEG)-block-poly(propylene fumarate) (PPF) diblock copolymers and poly(propylene fumarate) (PPF)-block-poly(ethylene glycol) (PEG)-block-poly(propylene fumarate) (PPF) triblock copolymers (and related methods for their making and use) that permits hydration for the formation of such things as hydrogels and has constrained and predictable material properties suitable for 3D printing and drug delivery applications. Using continuous digital light processing (cDLP) hydrogels the diblock and triblock copolymers can be photochemically printed from an aqueous solution into structures having a 10-fold increase in elongation at break compared to traditional diethyl fumarate (DEF) based printing. Furthermore, PPF-PEG-PPF triblock hydrogels have also been found in vitro to be biocompatible across a number of engineered MC3T3, NIH3T3, and primary Schwann cells.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention discloses application of dimethyl fumarate in preparation of a medicine for treating depression, and relates to the technical field of medicine research and development. Comprising experimental verification and medicine preparation, and the medicine preparation comprises the following steps: raw material preparation: weighing a dimethyl fumarate raw material and a medicinal carrier in proportion; uniformly mixing: fully mixing the dimethyl fumarate and the medicinal carrier by using a three-dimensional mixer or a double-cone mixer; granulating: adding a wetting agent for fluidized bed granulation or wet granulation to form granules with set sizes; granulating and drying: granulating the wet granules, drying, and controlling the water content of the granules; forming is conducted; and packaging: packaging the prepared medicine, and labeling information. The dimethyl fumarate is applied to the field of depression treatment, experiments verify that the dimethyl fumarate has a remarkable improvement effect on depression-like behaviors induced by chronic social contusion stress, and a new direction is provided for development of anti-depression drugs.

The invention discloses a composite phase-change heat storage material and a preparation method thereof. The composite phase-change heat storage material comprises the following raw materials in parts by mass: 50-70 parts of dimethyl fumarate, 25-40 parts of carbamide, 0.1-15 parts of heat-conducting material and 0.1-4 parts of nucleating agent; the preparation method comprises mixing dimethyl fumarate, carbamide, heat-conducting material and nucleating agent; the composite phase-change heat storage material has a phase change temperature of 69-91°C and a thermal enthalpy of 160-230 J / g; after 1000 cycles, the thermal performance attenuation of the phase-change heat storage material is less than 20%, the thermal stability is good, and the supercooling degree is less than 2°C; after adding the heat-conducting material, the thermal conductivity of the composite phase-change heat storage material is increased by 1.9-16 times compared with that when no heat-conducting material is added; the preparation process is simple, the raw materials are easy to obtain, and the composite phase-change heat storage material is suitable for mass production.

The present invention provides a method for synthesizing dimethyl fumarate and dimethyl maleate by dicarbonylation of acetylene, which uses acetylene, carbon monoxide and methyl nitrite as raw materials, and reacts them under the action of a supported palladium catalyst at a temperature of 60-200°C. o C. Under conditions of pressure of 0.1 to 6 MPa, acetylene is subjected to a double carbonylation reaction for 0.5 to 48 hours to obtain dimethyl fumarate and dimethyl maleate compounds. The present invention replaces methanol with methyl nitrite and employs a supported palladium catalyst, eliminating the need for any auxiliary agents and the direct use of O2. This avoids the problems of explosion limits, the use of corrosive auxiliary agents, and the separation and recycling of catalysts in the current double carbonylation of acetylene, overcoming the technical pain points of the prior art. Furthermore, the reaction has the advantages of high atomic utilization, mild reaction conditions, and high product yields. The byproduct, NO, can be recycled, making it suitable for industrial production and promising broad application prospects.

The invention belongs to the technical field of biological medicine, and provides dimethyl fumarate and application of a signal channel thereof in inhibition of arsenic-induced rat liver and kidney immune inflammation reaction. According to the present invention, with the application of the sodium arsenite in the rat liver and kidney immune inflammation reaction, the activation of the HMGB1 / TLR4 / NF-kappa B signal channel is inhibited through the intervention of the dimethyl fumarate, the Th1 / Th2 / Th17 / Treg balance disorder caused by the sodium arsenite and the CD4 + T cell subset differentiation disorder are antagonized, and the arsenic-induced rat liver and kidney immune inflammation reaction is alleviated; a rat subchronic arsenic exposure model is established, dimethyl fumarate is adopted for intervention, arsenic-induced liver and kidney tissue immune inflammatory response and CD4 + T cell subset differentiation disorder are discussed on the basis of an HMGB1 / TLR4 / NF-kappa B signal channel, and the antagonism and potential action mechanism of dimethyl fumarate in arsenic-induced rat immune injury are preliminarily clarified. And a theoretical basis and a research thought are provided for arsenic poisoning prevention and treatment.

The invention relates to a method for producing a biomonomer and a precursor for the biomonomer. A furoate carboxylation reaction is carried out with particles formed from a furoate and a base, and optionally a reaction accelerator. The particles may be in a slurry. The particles are exposed to gaseous carbon dioxide and heated. The reaction produces dicarboxylic acid esters that can be isolated and used to produce biomonomers, such as methyl furandicarboxylate and furandicarboxylic acid.

Systems and methods are provided that assess eye movement in multiple sclerosis (MS) patients receiving different drugs (e.g., dimethyl fumarate, fingolimod, clababine, ofarmumab) or treatments that (a) alleviate inflammation that may cause a symptom of multiple sclerosis and prevent nerve injury that may cause a symptom of multiple sclerosis); (b) testing sphingosine-1-phosphate receptor modulators that chelate lymphocytes in the lymphocyte nodes, preventing them from causing an autoimmune response); (c) checking for immunosuppressants acting on the lymphocyte pathway); and (d) analyzing the effect of the monoclonal antibody in inhibiting activation of lymphocyte B.

The invention provides a thermal expansion material, a resin liquid bridge plug and a deep shale gas shaft pressure-bearing plugging method. The thermal expansion material comprises a combination of any two or three of oxidative polymerization grafted 3-alkylthiophene modified thermal expansion microspheres, glycidyl methacrylate grafted modified thermal expansion microspheres and cinnamyl nitrile and diethyl fumarate cross-linked thermal expansion core-shell microspheres; by taking the total weight of the thermal expansion material as 100%, when the thermal expansion material comprises an oxidative polymerization grafted 3-alkylthiophene modified thermal expansion microsphere, a glycidyl methacrylate grafted modified thermal expansion microsphere and a cinnamyl nitrile and diethyl fumarate cross-linked thermal expansion core-shell microsphere, the contents of the three are respectively 15-55%, 25-75% and 30-65%. The thermal expansion material has good compatibility with resin liquid bridge plugs, can be uniformly dispersed in resin, does not agglomerate or settle, and can effectively inhibit the shrinkage of the resin through heat release expansion after solidification.

The application provides a polyester resin containing photoreactive dopamine and a preparation method and application thereof.The polyester resin containing photoreactive dopamine provided by the application is prepared from raw materials including dopamine methacrylamide (DMA), polypropylene fumarate (PPF), diethyl fumarate (DEF) and a photoinitiator.The dopamine molecules are integrated into the PPF crosslinking network structure through DMA, and the hydrophilicity of the material surface is significantly improved.The unsaturated polyester resin provided by the application can be applied to 3D printing technology based on face projection microstereolithography (PmuSL), the solidification forming process is simple, the three-dimensional structure is not limited, the application range is wide, and the final formed product can be used for further loading of bioactive substances, and has a wide application prospect in bone tissue engineering.The application further provides a preparation method and application of the polyester resin containing photoreactive dopamine.

Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.

To provide a novel anti-hepatitis B virus agent and related technologies.SOLUTION: The anti-hepatitis B virus agent comprises, as an active ingredient, dimethyl fumarate or a salt thereof.SELECTED DRAWING: None

The invention provides an industrialized efficient synthesis and cultivation method for cork oak truffle mycorrhizal seedlings, and relates to the field of synthesis and cultivation of cork oak truffle mycorrhizal seedlings. Comprising the following steps: 1, refrigerating truffles; step two, truffle is crushed, and dimethyl fumarate is added; step 3, preparing an inoculant and inoculating; 4, controlling the temperature and humidity of the environment according to a corresponding program, and standing for 48-72 hours; 5, placing and cultivating; compared with the prior art, the inoculation success rate of mycorrhizal seedlings is improved, and the infectious microbe infection rate and the production cost are reduced.

The invention discloses an application of a small molecule compound covalently bound with GSDMD in preparation of a pyroptosis inhibitor. Through deep research, a novel compound AF-966 / 00547018, called C6 for short, which can specifically target GSDMD protein and effectively inhibit the pore-forming activity of the GSDMD protein is screened, and the structure of the compound AF-966 / 00547018 is shown in the specification. Compared with reported pyroptosis inhibitors such as disulfiram, dimethyl fumarate and Necrosulfenamide (NSA), the C6 shows higher activity of inhibiting the pyroptosis of the cells, and the C6 shows higher activity of inhibiting the pyroptosis of the cells.

The invention relates to the technical field of medicines, in particular to application of dimethyl fumarate in promoting proliferation of amniotic fluid stem cells and application of dimethyl fumarate in promoting proliferation of amniotic fluid stem cells. The invention discloses an application of dimethyl fumarate as an NRF2 expression promoter. The administration concentration of the dimethyl fumarate is 2.5 to 10 M; the dimethyl fumarate promotes NRF2 expression, protects the amniotic fluid stem cells, reduces oxidative damage and accelerates proliferation of the amniotic fluid stem cells, the cell culture time is shortened to 72 hours, and the DMF monovalent value is 1 / 40 of that of a growth factor.

The invention discloses application of dimethyl fumarate in preparation of a medicine for preventing and / or treating skeletal muscle atrophy, and belongs to the field of medicine. It is proved for the first time that DMF can effectively relieve related symptoms of skeletal muscle atrophy caused by cancer cachexia, and a new thought is provided for treatment of skeletal muscle atrophy. The DMF can relieve skeletal muscle atrophy by reducing mitochondrial damage and improving mitochondrial homeostasis imbalance, and the potential mechanism of the DMF is possibly related to the regulation of HIF1alpha, mTOR and other pathways. In addition, DMF can improve cancer cachexia skeletal muscle atrophy and does not inhibit tumor growth, which indicates that DMF directly acts on skeletal muscle instead of tumor. Due to the common end characteristic of mitochondrial homeostasis imbalance and the like in amyotrophy caused by different causes (such as aging and drug toxicity), the adjusting effect of DMF on homeostasis in skeletal muscle can be expanded to be used for preventing and treating other types of amyotrophy, including amyotrophy caused by aging, glucocorticoid, chemotherapy drugs and the like. The invention provides an application basis for preventing and treating skeletal muscle atrophy by DMF.

The invention belongs to the field of drug activity, and particularly relates to application of dimethyl fumarate in preparation of alveolar cell regeneration drugs. The invention systematically evaluates the effect of dimethyl fumarate in the process of promoting pulmonary alveolar regeneration by constructing a pulmonary alveolar organ model and a bleomycin-induced lung injury mouse model. Research results show that dimethyl fumarate can significantly promote regeneration of alveolar epithelium AT2 cells, so that alveolar epithelium structure repair is accelerated.

The invention belongs to the technical field of medicines, and discloses application of sesquiterpenoids HHX shown in a formula (I) in preparation of medicines for preventing, relieving and / or treating autoimmune demyelination diseases. On a mouse experimental autoimmune encephalomyelitis model, HHX shows a very good treatment effect, and compared with a clinical drug dimethyl fumarate for multiple sclerosis, the HHX has the equivalent effect on improving EAE mouse disease scores, is more excellent in the aspects of improving suspension time and suspension grading, relieving myelitis infiltration and demyelination and the like, and has a good clinical application prospect. The potential of further transformation to clinical treatment is realized. # imgabs0 #

The invention relates to the technical field of biological medicines, and provides an application of dimethyl fumarate targeted GSDME in preparation of an anti-aging medicine. Dimethyl fumarate relieves the aging process by inhibiting the activity of GSDME, and can be used for developing and preparing anti-aging drugs.

The application discloses a kind of detection methods of dimethyl fumarate in food, it is related to chemical detection analysis technical field, comprising the following steps: S1, based on standard solution sample configuration standard curve;S2, the formula of purifying tube is selected and three representative samples, and based on purification scheme, sample is purified;S3, set two standard curve concentration points, carry out multiple sample data acquisition;S4, to three samples are detected in parallel double sample, and the detection limit level of sample, 1 times quantification limit level, 2 times quantification limit level and 5 times quantification limit level are 6 parallel standard addition test, based on experimental data is verified.The application makes that the dosage of organic reagent is saved about 80%, operation time is saved about 75%, the addition of internal standard DMM effectively calibrates the influence that target DMF changes with time and matrix interference, guarantees the result accuracy, while operation process is simple, to reduce the requirement of laboratory to personnel operation skill.

Examination of a test sample to determine the succination level of test sample is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of autoimmune disorders. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from an autoimmune disorder. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.

The invention discloses 4-octyl ester fumaric acid as well as a preparation method and application thereof. According to the invention, a new member 4-octyl ester fumaric acid is added for the research of fumaric acid derivatives. The method comprises the following steps: dissolving maleic anhydride and n-caprylic alcohol in ethyl acetate, and reacting at 90-100 DEG C for 10-20 hours to synthesize 4-octyl fumaric acid. The anti-inflammatory effect of the novel derivative 4-octyl fumaric acid is stronger than that of dimethyl fumarate.

The application provides application of nanosilver combined with an NRF2 inducer in treatment of multiple myeloma. Specifically, the nanosilver and the NRF2 inducer are combined, and in-vivo and in-vitro experiments are combined to explore the effect of the combination of the nanosilver and the NRF2 inducer on the multiple myeloma, and it is found that application of the NRF2 inducer promotes the inhibitory effect of the nanosilver on the multiple myeloma. In the application, the combination of the nanosilver and dimethyl fumarate can significantly increase the expression level of intracellular ROS, so that the multiple myeloma cells are in an over-oxidative stress state, thereby promoting cell apoptosis, which can provide a new option for future treatment of the multiple myeloma.

This invention discloses an antibacterial spinning oil suitable for acetate fibers used in cigarette filters, comprising an emulsifier, mineral oil, water, and an antibacterial agent. Before phase inversion, it is a transparent water-in-oil liquid; after phase inversion, it becomes a white oil-in-water emulsion. Phase inversion occurs in water or water containing the antibacterial agent. The mass ratio of the spinning oil to the water used for phase inversion or water containing the antibacterial agent before phase inversion is (1–49):(99–51). The antibacterial agent is a commercially available water-soluble antibacterial agent, selected from one or more of the following: 4-chloro-3-cresol, dichlorophenoxychlorophenol, bromochlorobisphenol, benzyl chloroethylammonium, benzalkonium chloride, dodecyl dimethyl ethylphenoxyethyl ammonium bromide, guanidine and guanidine polymers, quaternary ammonium salts, silver ions, copper ions, sodium phenylpropionate, nifedipine, dimethyl fumarate, sorbic acid, and dehydroacetic acid. The concentration of the antibacterial agent in water is 0.1 wt%–100 wt%.

The application discloses a lithium titanate battery and relates to the technical field of batteries.The battery comprises a positive electrode, a negative electrode, an electrolyte and a diaphragm, wherein the electrolyte is added with an adduct synthesized from dimethyl fumarate and benzidine in a specific molar ratio as a viscosity regulator, which effectively reduces the viscosity growth trend of the electrolyte at low temperature and improves the migration rate of lithium ions.The electrolyte further comprises lithium salt, organic solvent and auxiliary additives, which are beneficial to optimizing the low-temperature performance and cycle stability of the battery.The positive electrode active material is one or more of lithium iron phosphate, lithium manganate, lithium cobaltate or nickel-manganese-cobalt ternary material, and the negative electrode active material is lithium titanate, which is further combined with additives such as lithium nitrate and fluoroethylene carbonate, so that the capacity retention rate and charge-discharge efficiency of the battery at an extreme low temperature environment of-40 DEG C are significantly improved.The lithium titanate battery provided by the application has excellent low-temperature adaptability, safety and long cycle life, and is suitable for high-cold-area power batteries and energy storage system applications.

The invention relates to a preparation method of cyclobutane tetracarboxylic dianhydride, and belongs to the technical field of organic synthesis. The method comprises the steps of photochemical reaction, acidification reaction and anhydridation reaction. In the photochemical reaction, dimethyl fumarate is refined and then added into deionized water, the photochemical reaction is carried out through a UV lamp tube, and cyclobutane tetramethyl tetraformate is generated; the acidification reaction comprises the following steps: adding tetramethyl cyclobutane tetraformate into a hydrochloric acid solution, and carrying out hydrolysis reaction to generate cyclobutane tetracarboxylic acid; the anhydride reaction comprises the following steps: adding acetic anhydride and a PVP (Polyvinyl Pyrrolidone) crystallization aid into cyclobutane tetracarboxylic acid, and carrying out anhydride reaction to generate cyclobutane tetracarboxylic dianhydride; finally, through operations such as crystallization, filtration and pulping, the product purity is improved; the PVP crystallization auxiliary agent is prepared from an N-vinyl pyrrolidone monomer, 4-vinyl benzocyclobutene, allylidene triphenylphosphine and azodiisobutyronitrile, and the PVP crystallization auxiliary agent is prepared from the N-vinyl pyrrolidone monomer, the 4-vinyl benzocyclobutene, the allylidene triphenylphosphine and the The cyclobutane tetracarboxylic dianhydride prepared by the method is high in purity and high in total yield, and can meet the requirements of industrial large-scale production.

Examination of a test sample to determine the presence or quantity of succination of proteins is described. Examination can be via protein hydrolysis in total succination determination or via enzymatic digestion of isolated proteins and determination of the presence or quantity of modified peptides. The methods can be utilized for determination of excessive succination of lymph system proteins, which can be utilized in prevention or early detection of lymphopenia. Methods can be utilized for test samples of subjects under treatment with dimethyl fumarate suffering from multiple sclerosis. Methods can be utilized as a determination that treatment of the subject with DMF should be slowed or stopped.